🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Univar's (UNVR) Q2 Earnings Top Estimates, Revenues Miss

Published 08/07/2017, 09:15 PM
Updated 07/09/2023, 06:31 AM
BASFN
-
KRO
-
ARKAY
-
BASFY
-
UNVR
-
Univar (NYSE:UNVR) logged a profit (on a reported basis) of $31.3 million or 22 cents per share in second-quarter 2017, down around 21.4% from a profit of $39.8 million or 29 cents per share a year ago.

Barring one-time items, earnings came in at 34 cents per share in the quarter, beating the Zacks Consensus Estimate of 31 cents.

The chemical maker’s revenues dipped 0.7% year over year to $2,247 million in the reported quarter missing the Zacks Consensus Estimate of $2,266 million.

Gross profit rose around 4.6% year over year to $466.4 million in the quarter. Adjusted EBITDA margin increased 60 basis points to 7.2% with gains witnessed across all segments.
Univar Inc. Price, Consensus and EPS Surprise

Segment Review

Revenues from the USA division fell around 1.8% year over year to $1.2 billion in the reported quarter, as improvements in the company's sales force was largely offset by lower volumes. Gross profit rose 4.8% to $275.7 million in the reported quarter.

Revenues from the Canada segment went up around 1.4% to $492.4 million, driven by higher sales volumes, partly offset by changes in market and product mix resulting from a soft agricultural season. Gross profit rose roughly 11.4% to $67.5 million in the quarter.
The EMEA segment raked in sales of $463.7 million, up 0.8%, helped by mix enrichment and margin improvement actions that were partly offset by a decline in volume. Gross profit rose around 1.6% to $104.7 million, supported by favorable market mix and end market mix.
Sales from the Rest of World unit fell 4.4% to $99.8 million as a result of softer demand and sluggish economic conditions in Latin America. Gross profit was essentially flat year over year at $18.5 million.
Balance Sheet
Univar ended the quarter with cash and cash equivalents of $321.8 million, up around 4.4% year over year. Long-term debt was $2,895.5 million, down around 4.7% year over year.
Outlook
For the full year, Univar sees high-single digit growth in adjusted EBITDA. For third-quarter 2017, it expects adjusted EBITDA growth of high-single digits from previous year's third-quarter figure of $145.9 million.
Price Performance
Univar has significantly outperformed the industry over a year. The company’s shares have gained 60% over this period compared with the industry’s gain of 20.6% over the same period.
Zacks Rank & Other Stocks to Consider
Univar is a Zacks Rank #2 (Buy) stock.
Other top-ranked companies in the chemical space include BASFY SE (OTC:BASFY) , Kronos Worldwide (NYSE:KRO) and Arkema S.A. (OTC:ARKAY) .
BASF has an expected long-term earnings growth of 8.6% and flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Kronos Worldwide has an expected long-term earnings growth of 5% and sports a Zacks Rank #1.
Arkema has an expected long-term earnings growth of 12.8% and carries a Zacks Rank #2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>


BASF SE (DE:BASFN) (BASFY): Free Stock Analysis Report

Kronos Worldwide Inc (KRO): Free Stock Analysis Report

Arkema SA (ARKAY): Free Stock Analysis Report

Univar Inc. (UNVR): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.